SomaLogic, Inc. (SLGC) News
Filter SLGC News Items
SLGC News Results
|Loading, please wait...|
SLGC News Highlights
- For SLGC, its 30 day story count is now at 8.
- Over the past 25 days, the trend for SLGC's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about SLGC are MESA, SNAP and TECK.
Latest SLGC News From Around the Web
Below are the latest news stories about SomaLogic Inc that investors may wish to consider to help them evaluate SLGC as an investment opportunity.
No summary available.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
SomaLogic (SLGC) stated Friday that it expects its FY22 revenue to range between $105-$110M vs
BOULDER, Colo., Feb. 04, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4th, 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time. The event is intended to highlight recent corporate updates, technical specifications and capabilities of the SomaScan platform, and various applications across life science tools and clinical diagnostics. SomaLogic management will be joined by leadi
BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following virtual investor conferences. BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferencePresentation on Tuesday, February 15 at 10:30 a.m. ET11th Annual SVB Leerink Global Healthcare ConferencePresentation on Thursday, February 17 at 10:40 a.m. ET Interested parties may access a live and archived
SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study
Data will be available to researchers studying a wide range of disease statesBOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis (MESA) study beginning in the first quarter of 2022. SomaLogic will use its industry-leading assay to analyze 105 million protein measurements from 15,000 samples spanning 15 years of clinical
New York, NY, based Investment company Zweig-DiMenna Associates LLC (Current Portfolio) buys Caterpillar Inc, Macy's Inc, Teck Resources, Broadcom Inc, SomaLogic Inc, sells PayPal Holdings Inc, Electronic Arts Inc, Analog Devices Inc, Snap Inc, Capri Holdings during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Zweig-DiMenna Associates LLC.
SomaLogic (SLGC) preliminary unaudited revenue for the FY21 is expected to exceed $79M (consensus $78.37m), the upper end of SomaLogics previously raised 2021 revenue guidance
No summary available.
Presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern TimeBOULDER, Colo., Jan. 11, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31st, 2021. Preliminary, unaudited revenue for the full year 2021 is expected to exceed $79 million, the upper end of SomaLogic’s previously raised 2021 revenue guidance range